Suzhou Siyuan Pharmaceutical Technology

Suzhou Siyuan Pharmaceutical Technology is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of novel small molecule therapeutics for oncology. The company focuses on high-value biological targets within the DNA damage response (DDR) and ubiquitin-proteasome systems. Its lead program, SY-001, is a potent and selective inhibitor of Ubiquitin-specific protease 1 (USP1) currently in Phase 1 clinical trials for the treatment of advanced solid tumors. By leveraging its internal medicinal chemistry expertise and strategic location in the Suzhou Industrial Park, the company aims to deliver precision medicines to address significant unmet needs in cancer care.